Global health policies for hepatocellular carcinoma: a cross-sectional study
Author(s):
Douglas Chee 1, Christen En Ya Ong 2, Darren J H Tan 1, Jörn M Schattenberg 3, George N Ioannou 4, Daniel Q Huang 5; ; HCC Policy Study Group
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer death worldwide, with a median survival time under 12 months.1 Despite the availability of vaccinations and antiviral therapy to reduce the burden and morbidity of HCC,2,3 global HCC deaths continue to rise, related to poor disease awareness, the rising prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD),4,5 and increasing alcohol consumption. HCC surveillance, typically performed with ultrasound and α-fetoprotein in at-risk individuals, is associated with early diagnosis, curative treatment, and improved survival but is underutilized.6,7 Systemic policy changes may help prevent and mitigate the risk of HCC. However, a global overview of public health policies directed against HCC has not been reported.
Published online May 11, 2025
ارسال نظر